Ibogaine's Flagship Drug Hit a Cardiac Signal and a Lawsuit. A Different Drug Is Now Leading.

A company-by-company look at who holds ibogaine's 53 patents — and how the compound's original opioid-use-disorder program stalled over a cardiac safety signal and litigation, while a different drug, for a different disease, became the first ibogaine-class compound ever cleared for a US trial.

Ibogaine sits mid-table in our patent tracker: 15 granted, 38 pending, ahead of LSD and MDMA, behind DMT, 5-MeO-DMT, psilocybin, and ketamine. We've now covered psilocybin, 5-MeO-DMT, LSD, and ketamine from the same TREA pull. Ibogaine's story is messier than any of those — its foundational patents are almost exactly as old as the war on drugs, and the company holding the most ibogaine IP has spent the last several years split into two separate drug programs, one of which quietly failed and ended up in federal court.

Who's Actually Filing

Company	Compounds Covered	Granted	Pending	Est. Expiration
CaaMTech, LLC	Psilocybin, DMT, 5-MeO-DMT, Ibogaine	7	18	2038–2043
DemeRx, Inc.	Ibogaine	5	20	2031–2037
Atai Therapeutics, Inc.	Psilocybin, Ibogaine, DMT, 5-MeO-DMT	3	6	2042–2043
University of Minnesota	Ketamine, Ibogaine	2	1	2015–2038 (one already expired)
NDA International, Inc.	Ibogaine	2	0	2008–2010 (both expired)

Our data doesn't split DemeRx's patents between its two drug programs — see below for why that distinction matters more here than for any other compound in this series.

The Original Patents Belong to the Man Who Discovered the Effect

Howard Lotsof, an American addict-turned-researcher, noticed ibogaine's anti-addictive effect on himself in 1962 after taking it recreationally and finding his heroin withdrawal simply stopped. Twenty years later he patented it: US 4,499,096 in 1985, "Rapid Method for Interrupting the Narcotic Addiction Syndrome," followed by a series of additional patents through 1992 covering cocaine, amphetamine, alcohol, nicotine, and poly-drug dependency specifically. NDA International, the entity now holding what's left of that portfolio, shows 2 granted patents in our data — both already expired, in 2008 and 2010. Lotsof's original composition-of-matter claims on using ibogaine for addiction have been open prior art for over a decade. Everyone filing today is patenting something narrower: a specific metabolite, formulation, or treatment protocol layered on top of a discovery whose original patents ran out before most of today's companies existed.

DemeRx Split Into Two Drugs — and Only One Is Still Moving

DemeRx, Inc. holds the most ibogaine-specific IP in our dataset — 5 granted, 20 pending — but that figure spans two very different, now-separated drug programs, and the one that was actually named for the original opioid-addiction indication is the one that stalled.

The first program, run through a 2019 joint venture called DemeRx IB that atai Life Sciences backed with a $22 million investment, developed DMX-1002 — pharmaceutical-grade ibogaine hydrochloride, the actual parent compound — for opioid use disorder, the same indication Lotsof patented in the 1980s. An MHRA-approved Phase 1/2a trial in the UK dosed its first subject in 2021. Phase 1 results, reported by atai in August 2023, were mostly reassuring, but one of two participants at the highest dose showed QTc prolongation, a cardiac risk signal that resolved without intervention but was serious enough that the drug never advanced to Phase 2a. It has been absent from atai's pipeline updates since. AtaiBeckley (atai's successor entity) acquired the DemeRx IB joint venture outright in November 2023; DemeRx, Inc. subsequently sued ATAI Life Sciences in Delaware federal court in 2025, a dispute still pending.

The second program is the one we originally led with here: DMX-1001, oral noribogaine — ibogaine's primary active metabolite, not ibogaine itself — for alcohol use disorder, an entirely different indication. In April 2026, the FDA accepted DemeRx's IND application for DMX-1001, the first time the agency has authorized a US clinical trial of any ibogaine-class compound. A Phase 1 multiple-ascending-dose study reported positive safety, tolerability, and pharmacokinetics; a Phase 2 trial in AUD patients is targeted for 2027. Noribogaine's longer half-life is the pitch — sustained effects without redosing the parent compound's more acute cardiac profile, the exact problem that stalled DMX-1002.

So DemeRx is the largest ibogaine patent holder, and a DemeRx-linked drug is the first to reach a US trial — but it's not the drug, or the indication, that made ibogaine famous in the first place. The flagship program for opioid addiction is the one currently in litigation and off the pipeline.

The Rest of the Field

CaaMTech, the private Issaquah, WA prodrug chemistry company covered in our psilocybin piece, holds more combined patents than DemeRx (7 granted, 18 pending) but spread across four compounds — the same salts-and-prodrugs strategy it applies everywhere, not an ibogaine-specific program.

Atai Therapeutics, Inc. (Nasdaq: ATAI via parent AtaiBeckley) holds 3 granted and 6 pending, distinct from its parent entity's own separate filings (1 grant, 14 applications). Given atai's history with DemeRx IB above, this is likely the remainder of that same stalled opioid-use-disorder bet, not an unrelated side program. AtaiBeckley has separately agreed to be acquired by Eli Lilly, expected to close by late 2026 — that deal is built around BPL-003, AtaiBeckley's 5-MeO-DMT program, with no indication ibogaine factors into the rationale.

University of Minnesota rounds out the academic side: 2 granted (one already expired), 1 pending, spanning both ketamine and ibogaine research.

Where the Public Money Is Going

None of the current state-level ibogaine pushes show up in this patent data, because none of them are patent plays — they're funding mechanisms aimed at generating the clinical data DemeRx and everyone else will eventually need. Texas committed $50 million via its Ibogaine Initiative in 2025, though implementation has reportedly lagged the statute's requirements. Michigan's HB 6020 proposes joining a six-state consortium that would pool trial data toward one consolidated FDA submission. Separately, Stanford's MISTIC program has already published results from 30 Special Operations veterans treated with magnesium-ibogaine for traumatic brain injury, with no serious cardiac events reported — worth noting given DMX-1002's own cardiac signal came at a much higher, more sustained dose than that protocol uses. None of this generates new IP by itself, but it's the clinical evidence base that makes IP like DemeRx's worth something down the line.

The Pattern

Every other compound in this series has split cleanly into "who owns the IP" and "who's actually closest to approval," usually as two different companies making two different bets. Ibogaine looks that way on the surface — DemeRx is both the largest patent holder and tied to the first US-cleared trial — but the real split runs through DemeRx itself: one program, aimed at the addiction indication ibogaine was originally patented for, ran into a real cardiac safety signal and ended in a lawsuit; a second program, built around a different molecule entirely, is the one still standing. Whether the surviving drug ever treats the population ibogaine was famous for helping, or whether that requires someone restarting the ibogaine-proper program from scratch with better cardiac protocols, is the open question for whoever writes this update in a year.

This is business and regulatory reporting, not medical advice. DMX-1001 is not FDA-approved; ibogaine itself remains Schedule I and carries documented, serious cardiac risks requiring medical monitoring. No compound discussed here is approved for the indications mentioned.